Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study.
Visuri I, Eriksson C, Karlqvist S, Lykiardopoulos B, Karlén P, Grip O, Söderman C, Almer S, Hertervig E, Marsal J, Malmgren C, Delin J, Strid H, Sjöberg M, Bergemalm D, Hjortswang H, Halfvarson J.
Visuri I, et al. Among authors: sjoberg m.
Therap Adv Gastroenterol. 2023 May 30;16:17562848231174953. doi: 10.1177/17562848231174953. eCollection 2023.
Therap Adv Gastroenterol. 2023.
PMID: 37274297
Free PMC article.